Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor plus Neddylation Inhibitor

Pancreatic adenocarcinoma (PDAC) is the fourth most common cause of cancer death in the United States. PDAC is difficult to manage effectively, with a five-year survival rate of only 5%. PDAC is largely driven by activating KRAS mutations, and as such, cannot be directly targeted with therapeutic ag...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Ther
Hlavní autoři: Langdon, Casey G., Platt, James T., Means, Robert E., Iyidogan, Pinar, Mamillapalli, Ramanaiah, Klein, Michael, Held, Matthew A., Lee, Jong Woo, Koo, Ja Seok, Hatzis, Christos, Hochster, Howard S., Stern, David F.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457712/
https://ncbi.nlm.nih.gov/pubmed/28292938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0794
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky